Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis.
The biosynthesis of peptidoglycan is essential for all bacteria and has no counterpart in eukaryotic cells. It is one of the prime targets for antibiotic chemotherapy, especially phospho-MurNAc-pentapeptide translocase (translocase I) is a fascinating target in which there is no commercial antibiotic. In this review we will describe three nucleoside translocase I inhibitors, mureidomycin, tunicamycin and liposidomycin.
Department of Agro-Bioscience, Iwate University, Iwate 020-8550, Japan.
Ken-ichi
K
Kimura
Timothy D H
TD
Bugg
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D002473:Cell Wall / Q000187:drug effects / Q000378:metabolism; D015394:Molecular Structure; D009705:Nucleosides / Q000494:pharmacology; D010457:Peptidoglycan / Q000096:biosynthesis* / Q000187:drug effects; D017855:Transferases (Other Substituted Phosphate Groups) / Q000378:metabolism; D014415:Tunicamycin / Q000494:pharmacology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D009705:Nucleosides; D010457:Peptidoglycan; C047544:liposidomycins; D014415:Tunicamycin; D017855:Transferases (Other Substituted Phosphate Groups); C100130:phospho-N-acetylmuramoyl pentapeptide transferase